OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Milei Threatens Falkland Oil Firms With Sanctions 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Add as a preferred source on Google
TUSTIN, Calif., March 07, 2018 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred Stock is payable on April 2, 2018 to holders of record at the close of business on March 19, 2018.
The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share, which is equivalent to an annualized 10.50% per share, based on the $25.00 per share stated liquidation preference, accruing from January 1, 2018 through March 31, 2018. The Series E Preferred Stock is listed on the NASDAQ Capital Market and trades under the ticker symbol "CDMOP".
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With nearly 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
